Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P029. Inflammasome activation P2X7-dependent in Crohn's disease
Authors:

A. Zelante1, R. Borgoni2, R. D'Incà3, G.C. Sturniolo3, J.F. Blume1, G. Donvito4, S. Falzoni4, F. Di Virgilio4, 1University Hospital Sant'Anna, Medicine, Ferrara, Italy, 2University of Milano-Bicocca, Department of Statistics, Milan, Italy, 3University of Padua, Department of Surgical, Oncological and Gastroenterological Sciences, Padua, Italy, 4University of Ferrara, Department of Experimental and Diagnostic Medicine, Ferrara, Italy

P029. Normalization of mucosal TNF-alpha as a criterion when to stop treatment with anti TNF in UC patients? A preliminary report
P029. Oral iron supplementation promotes inflammation and colorectal carcinogenesis in a mouse model of colitis-associated cancer
P029

Amyloidosis in Inflammatory Bowel Disease: Preliminary Results of screening in a selected population

Authors:

O. Tayfur Yurekli*1, N.S. Buyukasik1, S. Orhun Yavuz2, M. Tahtaci1, A. Demirezer Bolat1, F.E. Akin1, H. Koseoglu1, M. Basaran1, E. Selvi1, O. Ersoy1

1Ankara Ataturk Research and Education Hospital, Gastroenterology, Ankara, Turkey, 2Ankara Ataturk Research and Education Hospital, Pathology, Ankara, Turkey

P030.

Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation

Authors:

W. Wu1, C. Liu1, P.-C. Yang2, Z. Liu1, 1Shanghai Tenth People's Hospital, Tongji University, Department of Gastroenterology, Shanghai, China, 2Shenzhen University School of Medicine, Shenzhen Key Laboratory of Allergy & Immunology, Shenzhen, China

P030. High fat diet aggravates Crohn's disease-like ileitis independently of obesity via alterations of epithelial barrier homeostasis
Authors:

L. Gruber1, S. May1, J. Fiamoncini2, V. Müller2, M. Lichtenegger3, M. Rychlik3, H. Daniel2, D. Haller1, 1Technical University Munich, Biofunctionality, ZIEL – Research Center for Nutrition and Food Sciences, CDD – Research Center for Diet and Disease, Freising, Germany, 2Technical University Munich, Department of Biochemistry, ZIEL – Research Center for Nutrition and Food Sciences, Freising, Germany, 3Technical University Munich, Bioanalytics, ZIEL – Research Center for Nutrition and Food Sciences, Freising, Germany

P030. Interaction between glycans and the immune system: Do glycans play a role in Crohn's disease pathogenesis?
P030. Mucosal cytokine profiles in inflammatory bowel disease patients
P030

Analysis of the protease MT1-MMP as therapeutic target in IBD

Authors:

A. Koziol*1, P. Gonzalo1, A. Pollán1, N. Nuñez-Andrade1, P.M. Linares2, M.E. Fernández-Contreras2, M. Chaparro2, A. Urzainqui3, A. Urzainqui3, F. Sánchez-Madrid3, J.P. Gisbert2, A. Arroyo1

1Centro Nacional de Investigaciones Cardiovasculares (CNIC), Vascular Biology and Inflammation Department, Madrid, Spain, 2Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 3Hospital Universitario de La Princesa and IP , Immunology Unit, Madrid, Spain

P031.

Probiotic bacteria enhance antigen sampling and processing by dendritic cells in pediatric IBD

Authors:

C. Strisciuglio, E. Miele, F.P. Giugliano, S. Vitale, M. Andreozzi, A. Vitale, S. Cenni, A. Staiano, R. Troncone, C. Gianfrani, University Federico II, Department of Translational and Medical Science, Naples, Italy

P031. Induction of an M2 macrophage phenotype by the HDAC inhibitor ITF2357
P031. Mucosal immune environment in colonic carcinogenesis: T-cell activation in ulcerative colitis and dysplasia
P031. Simultaneously restoration of Foxp3 (+) regulatory T cells subsets, type 1-like regulatory T cells and B cells correlates with clinical response to infliximab therapy for IBD
Authors:

Z. Li1, S. Vermeire1, D. Bullens2, M. Ferrante1, K. Van Steen3, M. Noma1, P. Rutgeerts1, J.L. Ceuppens2, G. Van Assche4, 1Catholic University of Leuven, IBD Group, Division of Gastroenterology, Leuven, Belgium, 2Catholic University of Leuven, Lab of Clinical Immunology, Leuven, Belgium, 3University de Liège, Dept of Bioinformatics-Statistical Genetics, Liège, Belgium, 4Catholic University of Leuven, IBD Group, Division of Gastroenterology, Lab of Clinical Immunology, Leuven, Belgium

P031

GPR84 inhibition as a novel therapeutic approach in IBD: mechanistic and translational studies

Authors:

S. Dupont1, I. Arijs2, R. Blanqué1, D. Laukens3, K. Nys2, M.C. Ceccotti4, D. Merciris4, S. De Vos5, O. Maté6, I. Parent1, V. De Vriendt5, F. Labéguère7, R. Galien1, M. Devos3, P. Rutgeerts2, N. Vandeghinste8, S. Vermeire2, R. Brys*8

1Galapagos SASU, Translational Science, Romainville, France, 2Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in GastroIntestinal Disorders, Leuven, Belgium, 3Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium, 4Galapagos SASU, in vivo pharmacology, Romainville, France, 5Galapagos NV, Cell-based Assays, Mechelen, Belgium, 6Galapagos NV, Bioinformatics, Mechelen, Belgium, 7Galapagos SASU, Medicinal Chemistry, Romainville, France, 8Galapagos NV, Therapeutic Area Group, Mechelen, Belgium

P032. 5-ASA inhibits phospholipase D-dependent mammalian target of rapamycin signaling in colorectal cancer
P032.

Pro-inflammatory cytokines induce the expression of TL1A/TNFSF15 in primary intestinal subepithelial myofibroblasts

Authors:

G. Bamias1, E. Filidou2, D. Goukos3, V. Valatas4, K. Arvanitidis2, M. Panagopoulou2, G. Kouklakis5, G. Daikos3, S. Ladas1, G. Kolios2, 1Laikon Hospital, Ethnikon & Kapodistriakon University of Athens, Academic Dpt. of Gastroenterology, Athens, Greece, 2Democritus University of Thrace, Laboratory of Pharmacology, Faculty of Medicine, Alexandroupolis, Greece, 3Laikon Hospital, Ethnikon & Kapodistriakon University of Athens, 1st. Dpt of Propaedeutic and Internal Medicine, Laboratory of Infectious Diseases, Athens, Greece, 4University of Crete, Laboratory of Gastroenterology, Faculty of Medicine, Heraklion, Greece, 5Democritus University of Thrace, Endoscopy Unit, Faculty of Medicine, University Hospital of Alexandroupolis, Alexandroupolis, Greece

P032. Genetic deletion and pharmacological inhibition of chemokine receptor 9 (CCR9) result in opposite effects on the development of oral tolerance
P032. Serum hepcidin in inflammatory bowel diseases
Authors:

A. Di Sabatino1, G. Bergamaschi1, R. Albertini1, F. Costanzo1, M. Guerci1, M. Masotti1, A. Pasini1, P. Giuffrida1, P. Biancheri1, N. Campostrini2, M. Corbella2, D. Girelli2, G.R. Corazza1, 1IRCCS Policlinico San Matteo, Pavia, Italy, 2Department of Medicine, Verona, Italy

P032

Pharmacokinetic Properties of RPC1063, a Selective S1P1 and S1P5 Receptor Agonist, Significantly Contribute to Efficacy in Animal Models of Inflammatory Bowel Disease

Authors:

F. Scott1, B. Clemons1, H. Dedman2, R. Powell2, E. Martinborough3, G. Timony2, M. Boehm3, R. Peach*1

1Receptos, Biology, San Diego, United States, 2Receptos, Preclinical Sciences, San Diego, United States, 3Receptos, Chemistry, San Diego, United States

P033.

Prevention of recurrent Clostridium difficile infection by neutralizing monoclonal antibodies in a hamster relapse model

Authors:

D. Staelens1, M. Van de Wouwer2,3, E. Brouwers3, S. Caluwaerts4, P. Rottiers4, P. Vanhoenacker4, N. Geukens2, P.J. Declerck3, M. Ferrante1, S. Vermeire1, P. Rutgeerts1, G. Van Assche1, 1Translational Research in GastroIntestinal Disorders, Department of Clinical and Experimental Medicine, Leuven, Belgium, 2PharmAbs, PharmAbs, Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium, 4ActoGeniX, ActoGeniX, Zwijnaarde, Belgium